Nanoscale analysis of protein and peptide absorption: Insulin absorption using complexation and pH-sensitive hydrogels as delivery vehicles

European Journal of Pharmaceutical Sciences

Volumn 29, Issue 3-4 SPEC. ISS., 2006, Pages 183-197

  Peppas, Nicholas A ^a,b   Kavimandan, Nikhil J ^a  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Nanoparticles; Nanotechnology; Protein delivery

Indexed keywords

APROTININ; BACTERIAL TOXIN; CALCITONIN; CARBOMER; CHELATING AGENT; CHYMOTRYPSIN; COPOLYMER; DIDECANOYL LEVO ALPHA PHOSPHATIDYLCHOLINE; EDETIC ACID; INSULIN; LECTIN; MACROGOL; OXYTOCIN; PENETRATION ENHANCING AGENT; PEPTIDE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; POLIDOCANOL; POLY(METHACYLIC ACID CO ETHYLENE GLYCOL); POLYACRYLIC ACID; POLYCARBOPHIL; POLYMER; PROTEIN; PROTEINASE INHIBITOR; SURFACTANT; TRANSFERRIN; TRYPSIN; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONA OCCLUDENS TOXIN;

ARTICLE; CARCINOMA; COMPLEX FORMATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG INDUCED CANCER; DRUG METABOLISM; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; HUMAN; HYDROGEL; HYPERINSULINEMIA; HYPERTROPHY; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SYNTHESIS; INSULIN TREATMENT; INTESTINE EPITHELIUM CELL; INTESTINE VILLUS; LIVER METABOLISM; NANOTECHNOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOSE INJURY; NOSE IRRITATION; ORAL GLUCOSE TOLERANCE TEST; PANCREAS HYPERTROPHY; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL HYPERPLASIA; PANCREAS ISLET TRANSPLANTATION; PATIENT COMPLIANCE; PH; PRIORITY JOURNAL; STRUCTURE ANALYSIS; ULTRASOUND;

ABSORPTION; ADMINISTRATION, BUCCAL; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; HYDROGELS; HYDROGEN-ION CONCENTRATION; INSULIN; NANOTECHNOLOGY; PHARMACEUTICAL VEHICLES; VEHICLES;

EID: 33750177969     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.04.014     Document Type: Article

References (127)

1. Anon., 1999. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation, Part 1: Diagnosis and Classification of Diabetes Mellitus. World Health Organization, Geneva.
2. Amos A.F., McCarty D.J., and Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diab. Med. 14 Suppl. 5 (1997) S1-S85
3. Anderson J.M., and Van Itallie C.M. Tight junctions and the molecular basis for regulation of paracellular permeability. Am. J. Physiol. 269 (1995) G467-G475
4. Anthony S., Odgers T., and Kelly W. Health promotion and health education about diabetes mellitus. J. R. Soc. Health 124 (2004) 70-73
5. Arbit E. The physiological rationale for oral insulin administration. Diab. Technol. Ther. 6 (2004) 510-517
6. 2EDTA, and aprotinin on rectal, nasal, and buccal insulin delivery. Pharm. Res. 5 (1988) 305-308
7. Azari P.R., and Feeney R.E. Resistance of metal complexes of conalbumin and transferrin to proteolysis and to thermal denaturation. J. Biol. Chem. 232 (1958) 293-302
8. Bai J.P., Chang L.L., and Guo J.H. Effects of polyacrylic polymers on the degradation of insulin and peptide drugs by chymotrypsin and trypsin. J. Pharm. Pharmacol. 48 (1996) 17-21
9. Ballinger W.F., and Lacy P.E. Transplantation of intact pancreatic islets in rats. Surgery 72 (1972) 175-186
10. Banerjee D., Flanagan P.R., Cluett J., and Valberg L.S. Transferrin receptors in the human gastrointestinal tract. Relationship to body iron stores. Gastroenterology 91 (1986) 861-869
11. Barnett A.H., and Owens D.R. Insulin analogues. Lancet 349 (1997) 47-51
12. Baudry B., Fasano A., Ketley J., and Kaper J.B. Cloning of a gene (zot) encoding a new toxin produced by Vibrio cholerae. Infect. Immun. 60 (1992) 428-434
13. Benjamin S.M., Valdez R., Geiss L.S., Rolka D.B., and Narayan K.M. Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention. Diab. Care 26 (2003) 645-649
14. Bernkop-Schnurch A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J. Control. Rel. 52 (1998) 1-16
15. Beyer U., Roth T., Schumacher P., Maier G., Unold A., Frahm A.W., Fiebig H.H., Unger C., and Kratz F. Synthesis and in vitro efficacy of transferrin conjugates of the anticancer drug chlorambucil. J. Med. Chem. 41 (1998) 2701-2708
16. Bolli G.B., Di Marchi R.D., Park G.D., Pramming S., and Koivisto V.A. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 42 (1999) 1151-1167
17. Bouwens L. Islet morphogenesis and stem cell markers. Cell Biochem. Biophys. 40 (2004) 81-88
18. Brange J., and Volund A. Insulin analogs with improved pharmacokinetic profiles. Adv. Drug Deliv. Rev. 35 (1999) 307-335
19. Broadwell R.D., Baker-Cairns B.J., Friden P.M., Oliver C., and Villegas J.C. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor. Exp. Neurol. 142 (1996) 47-65
20. Cefalu W.T. Concept, strategies, and feasibility of noninvasive insulin delivery. Diab. Care 27 (2004) 239-246
21. Cefalu W.T., Rosenstock J., and Bindra S. Inhaled insulin: a novel route for insulin delivery. Expert Opin. Investig. Drugs 11 (2002) 687-691
22. Cevc G., Gebauer D., Stieber J., Schatzlein A., and Blume G. Ultraflexible vesicles, transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim. Biophys. Acta 1368 (1998) 201-215
23. Clark M.A., Hirst B.H., and Jepson M.A. Lectin-mediated mucosal delivery of drugs and microparticles. Adv. Drug Deliv. Rev. 43 (2000) 207-223
24. Clement S., Dandona P., Still J.G., and Kosutic G. Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial. Metabolism 53 (2004) 54-58
25. de Groot M., Schuurs T.A., and van Schilfgaarde R. Causes of limited survival of microencapsulated pancreatic islet grafts. J. Surg. Res. 121 (2004) 141-150
26. Denker B.M., and Nigam S.K. Molecular structure and assembly of the tight junction. Am. J. Physiol. 274 (1998) F1-F9
27. Dominguez L.J., and Licata G. The discovery of insulin: what really happened 80 years ago. Ann. Ital. Med. Int. 16 (2001) 155-162
28. Drejer K., Vaag A., Bech K., Hansen P., Sorensen A.R., and Mygind N. Intranasal administration of insulin with phospholipid as absorption enhancer: pharmacokinetics in normal subjects. Diab. Med. 9 (1992) 335-340
29. Fasano A. Novel approaches for oral delivery of macromolecules. J. Pharm. Sci. 87 (1998) 1351-1356
30. Fasano A., and Uzzau S. Modulation of intestinal tight junctions by zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J. Clin. Invest. 99 (1997) 1158-1164
31. Foldvari M. Non-invasive administration of drugs through the skin: challenges in delivery system design. Pharm. Sci. Technol. Today 3 (2000) 417-425
32. Gabbe S.G., and Graves C.R. Management of diabetes mellitus complicating pregnancy. Obstet. Gynecol. 102 (2003) 857-868
33. Gabor F., Schwarzbauer A., and Wirth M. Lectin-mediated drug delivery: binding and uptake of BSA-WGA conjugates using the Caco-2 model. Int. J. Pharm. 237 (2002) 227-239
34. Gabor F., Stangl M., and Wirth M. Lectin-mediated bioadhesion: binding characteristics of plant lectins on the enterocyte-like cell lines Caco-2, HT-29 and HCT-8. J. Control. Rel. 55 (1998) 131-142
35. Gabor F., Wirth M., Jurkovich B., Haberl I., Theyer G., Walcher G., and Hamilton G. Lectin-mediated bioadhesion: proteolytic stability and binding-characteristics of wheat germ agglutinin and Solanum tuberosum lectin on Caco-2, HT-29 and human colonocytes. J. Control. Rel. 49 (1997) 27-37
36. Ganong W. Review of Medical Physiology (1995), Appleton & Lange, Stamford, CT
37. Genuth S., Alberti K.G., Bennett P., Buse J., Defronzo R., Kahn R., Kitzmiller J., Knowler W.C., Lebovitz H., Lernmark A., Nathan D., Palmer J., Rizza R., Saudek C., Shaw J., Steffes M., Stern M., Tuomilehto J., and Zimmet P. Follow-up report on the diagnosis of diabetes mellitus. Diab. Care 26 (2003) 3160-3167
38. Goldraich M., and Kost J. Glucose-sensitive polymeric matrices for controlled drug delivery. Clin. Mater. 13 (1993) 135-142
39. Gordon G.S., Moses A.C., Silver R.D., Flier J.S., and Carey M.C. Nasal absorption of insulin: enhancement by hydrophobic bile salts. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 7419-7423
40. Group U.P.D.S. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
41. Guevara-Aguirre J., Guevara M., Saavedra J., Mihic M., and Modi P. Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study. Diab. Metab. Res. Rev. 20 (2004) 472-478
42. Hayakawa E., Yamamoto A., Shoji Y., and Lee V.H. Effect of sodium glycocholate and polyoxyethylene-9-lauryl ether on the hydrolysis of varying concentrations of insulin in the nasal homogenates of the albino rabbit. Life Sci. 45 (1989) 167-174
43. Heinemann L., Pfutzner A., and Heise T. Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr. Pharm. Des. 7 (2001) 1327-1351
44. Hermansen K., Ronnemaa T., Petersen A.H., Bellaire S., and Adamson U. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diab. Care 27 (2004) 162-167
45. Hill R.A., Strat A.L., Hughes N.J., Kokta T.J., Dodson M.V., and Gertler A. Early insulin signaling cascade in a model of oxidative skeletal muscle: mouse Sol8 cell line. Biochim. Biophys. Acta 1693 (2004) 205-211
46. Hussain M.A., and Theise N.D. Stem-cell therapy for diabetes mellitus. Lancet 364 (2004) 203-205
47. Ichikawa H., and Peppas N.A. Novel complexation hydrogels for oral peptide delivery: in vitro evaluation of their cytocompatibility and insulin-transport enhancing effects using Caco-2 cell monolayers. J. Biomed. Mater. Res. 67A (2003) 609-617
48. Jones A.T., Gumbleton M., and Duncan R. Understanding endocytic pathways and intracellular trafficking: a prerequisite for effective design of advanced drug delivery systems. Adv. Drug Deliv. Rev. 55 (2003) 1353-1357
49. Kan K.S., and Coleman R. The calcium ionophore A23187 increases the tight-junctional permeability in rat liver. Biochem. J. 256 (1988) 1039-1041
50. Kilpatrick D.C., Pusztai A., Grant G., Graham C., and Ewen S.W.B. Tomato lectin resists digestion in the mammalian alimentary canal and binds to intestinal villi without deleterious effects. FEBS Lett. 185 (1985) 299-305
51. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diab. Care 21 (1998) 1414-1431
52. Kissel T., and Werner U. Nasal delivery of peptides: an in vitro cell culture model for the investigation of transport and metabolism in human nasal epithelium. J. Control. Rel. 53 (1998) 195-203
53. Lafont J., Rouanet J.M., Gabrion J., Assouad J.L., Zambonino Infante J.L., and Besancon P. Duodenal toxicity of dietary phaseolus vulgaris lectins in the rat: an integrative assay. Digestion 41 (1988) 83-93
54. Langkjaer L., Brange J., Grodsky G.M., and Guy R.H. Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment. J. Control. Rel. 51 (1998) 47-56
55. Le L., Kost J., and Mitragotri S. Combined effect of low-frequency ultrasound and iontophoresis: applications for transdermal heparin delivery. Pharm. Res. 17 (2000) 1151-1154
56. Lee V.H., Yamamoto A., and Kompella U.B. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit. Rev. Ther. Drug Carrier Syst. 8 (1991) 91-192
57. Lee V.H.L., and Yamamoto A. Penetration and enzymatic barriers to peptide and protein absorption. Adv. Drug Deliv. Rev. 4 (1989) 171-207
58. Lehr C.M. Lectin-mediated drug delivery: the second generation of bioadhesives. J. Control. Rel. 65 (2000) 19-29
59. Lillioja S., Mott D.M., Spraul M., Ferraro R., Foley J.E., Ravussin E., Knowler W.C., Bennett P.H., and Bogardus C. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N. Engl. J. Med. 329 (1993) 1988-1992
60. Lowman A.M., Morishita M., Kajita M., Nagai T., and Peppas N.A. Oral delivery of insulin using pH-responsive complexation gels. J. Pharm. Sci. 88 (1999) 933-937
61. Lowman A.M., and Peppas N.A. Analysis of the complexation/decomplexation phenomena in graft copolymer networks. Macromolecules 30 (1997) 4959-4965
62. Lowman A.M., Morishita M., Peppas N.A., and Nagai T. Novel bioadhesive complexation networks for oral protein drug delivery. In: McCulloch I., and Shalaby S.W. (Eds). Materials for Controlled Release Applications (1998), American Chemical Society, Washington, DC 156-164
63. Luessen H.L., Rentel C.O., Kotze A.F., Lehr C.M., de Boer A.G., Verhoef J.C., and Junginger H.E. Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro. J. Control. Rel. 45 (1997) 15-23
64. Madara J.L., and Trier J.S. Functional morphology of the mucosa of the small intestine. In: Johnson L.R. (Ed). Physiology of the Gastrointestinal Tract (1986), Raven Press, New York 1209-1250
65. Madsen F., and Peppas N.A. Complexation graft copolymer networks: swelling properties, calcium binding and proteolytic enzyme inhibition. Biomaterials 20 (1999) 1701-1708
66. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Br. Med. J. 314 (1997) 1512-1515
67. McAulay V., and Frier B.M. Insulin analogues and other developments in insulin therapy for diabetes. Expert Opin. Pharmacother. 4 (2003) 1141-1156
68. McCarthy A.A. New approaches to diabetes disease control, insulin delivery, and monitoring. Chem. Biol. 11 (2004) 1597-1598
69. McChesney L.P. Advances in pancreas transplantation for the treatment of diabetes. Dis. Mon. 45 (1999) 88-100
70. Mellman I., Fuchs R., and Helenius A. Acidification of the endocytic and exocytic pathways. Ann. Rev. Biochem. 55 (1986) 663-700
71. Mitragotri S., Blankschtein D., and Langer R. Ultrasound-mediated transdermal protein delivery. Science 269 (1995) 850-853
72. Modi P., Mihic M., and Lewin A. The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist System. Diab. Metab. Res. Rev. 18 Suppl. 1 (2002) S38-S42
73. Mohan V. Which insulin to use? Human or animal?. Curr. Sci. 83 (2002) 1544-1547
74. Morishita M., Lowman A.M., Takayama K., Nagai T., and Peppas N.A. Elucidation of the mechanism of incorporation of insulin in controlled release systems based on complexation polymers. J. Control. Rel. 81 (2002) 25-32
75. 2EDTA and sodium glycocholate on intestinal absorption of insulin. Biol. Pharm. Bull. 16 (1993) 68-72
76. Mudaliar S., and Edelman S.V. Insulin therapy in type 2 diabetes. Endocrinol. Metab. Clin. N. Am. 30 (2001) 935-982
77. Mun G.A., Nurkeeva Z.S., Khutoryanskiy V.V., Sergaziyev A.D., and Rosiak J.M. Radiation synthesis of temperature-responsive hydrogels by copolymerization of [2-(methacryloyloxy)ethyl]trimethylammonium chloride with N-isopropylacrylamide. Radiat. Phys. Chem. 65 (2002) 67-70
78. Nagahora H., Harata K., Muraki M., and Jigami Y. Site-directed mutagenesis and sugar-binding properties of the wheat germ agglutinin mutants Tyr73Phe and Phe116Tyr. Eur. J. Biochem. 233 (1995) 27-34
79. Nagai T. Topical mucosal adhesive dosage forms. Med. Res. Rev. 6 (1986) 227-242
80. Naisbett B., and Woodley J. Binding of tomato lectin to the intestinal mucosa and its potential for oral drug delivery. Biochem. Soc. Trans. 18 5 (1990) 879-880
81. Nam I.K., Mun G.A., Urkimbaeva P.I., and Nurkeeva Z.S. Gamma-induced synthesis of hydrogels of vinyl ethers with stimuli-sensitive behavior. Radiat. Phys. Chem. 66 (2003) 281-287
82. Noah N.D., Bender A.E., Reaidi G.B., and Gilbert R.J. Food poisoning from raw red kidney beans. Br. Med. J. 281 (1980) 236-237
83. Nolte M.S., Taboga C., Salamon E., Moses A., Longenecker J., Flier J., and Karam J.H. Biological activity of nasally administered insulin in normal subjects. Horm. Metab. Res. 22 (1990) 170-174
84. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., Kojima Y., Furuyoshi N., and Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diab. Res. Clin. Pract. 28 (1995) 103-117
85. Oliva A., Farina J., and Llabres M. Development of two high-performance liquid chromatographic methods for the analysis and characterization of insulin and its degradation products in pharmaceutical preparations. J. Chromatogr. B Biomed. Sci. Appl. 749 (2000) 25-34
86. Opara E.C., and Kendall Jr. W.F. Immunoisolation techniques for islet cell transplantation. Expert Opin. Biol. Ther. 2 (2002) 503-511
87. Owens D.R. New horizons-alternative routes for insulin therapy. Nat. Rev. Drug Discov. 1 (2002) 529-540
88. Owens D.R., Zinman B., and Bolli G. Alternative routes of insulin delivery. Diab. Med. 20 (2003) 886-898
89. Owens D.R., Zinman B., and Bolli G.B. Insulins today and beyond. Lancet 358 (2001) 739-746
90. Park K.S. Prevention of type 2 diabetes mellitus from the viewpoint of genetics. Diab. Res. Clin. Pract. 66 Suppl. 1 (2004) S33-S35
91. Patton J.S., Bukar J., and Nagarajan S. Inhaled insulin. Adv. Drug Deliv. Rev. 35 (1999) 235-247
92. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 23 (2000) 101-113
93. Peppas N.A., and Klier J. Controlled release by using poly(methacrylic acid-g-ethylene glycol) hydrogels. J. Control. Rel. 16 (1991) 203-214
94. Peppas N.A., and Lowman A.M. Protein delivery from novel bioadhesive complexation hydrogels. In: Frøkjær S., Christup L., and Krogsgaard-Larsen P. (Eds). Protein and Peptide Drug Research (1998), Munksgaard, Copenhagen 206-216
95. Podual K., Doyle III F.J., and Peppas N.A. Dynamic behavior of glucose oxidase-containing microparticles of poly(ethylene glycol)-grafted cationic hydrogels in an environment of changing pH. Biomaterials 21 (2000) 1439-1450
96. Ponchel G., and Irache J. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev. 34 (1998) 191-219
97. Qian Z.M., Li H., Sun H., and Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54 (2002) 561-587
98. Qiu Y., and Park K. Environment-sensitive hydrogels for drug delivery. Adv. Drug Deliv. Rev. 53 (2001) 321-339
99. Reseland J.E., Holm H., Jacobsen M.B., Jenssen T.G., and Hanssen L.E. Proteinase inhibitors induce selective stimulation of human trypsin and chymotrypsin secretion. J. Nutr. 126 (1996) 634-642
100. Rini J.M. Lectin structure. Biophys. J. 24 (1995) 551-577
101. Rubas W., Cromwell M.E., Shahrokh Z., Villagran J., Nguyen T.N., Wellton M., Nguyen T.H., and Mrsny R.J. Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. J. Pharm. Sci. 85 (1996) 165-169
102. Sajeesh S., and Sharma C.P. Poly methacrylic acid-alginate semi-IPN microparticles for oral delivery of insulin: a preliminary investigation. J. Biomater. Appl. 19 (2004) 35-45
103. Salzman R., Manson J.E., Griffing G.T., Kimmerle R., Ruderman N., McCall A., Stoltz E.I., Mullin C., Small D., Armstrong J., et al. Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type I diabetes. N. Engl. J. Med. 312 (1985) 1078-1084
104. Sanger F. Chemistry of insulin; determination of the structure of insulin opens the way to greater understanding of life processes. Science 129 (1959) 1340-1344
105. Sayani A.P., and Chien Y.W. Systemic delivery of peptides and proteins across absorptive mucosae. Crit. Rev. Ther. Drug Carrier Syst. 13 (1996) 85-184
106. Scott D.A. Crystalline insulin. Biochem. J. 28 (1934) 1592-1602
107. Shah D., and Shen W.C. Transcellular delivery of an insulin-transferrin conjugate in enterocyte-like Caco-2 cells. J. Pharm. Sci. 85 (1996) 1306-1311
108. Shapiro A.M., Lakey J.R., Ryan E.A., Korbutt G.S., Toth E., Warnock G.L., Kneteman N.M., and Rajotte R.V. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343 (2000) 230-238
109. Shen W.-C., Wan J., and Ekrami H. (C) Means to enhance penetration: (3) Enhancement of polypeptide and protein absorption by macromolecular carriers via endocytosis and transcytosis. Adv. Drug Deliv. Rev. 8 (1992) 93-113
110. Simpson R.W., Shaw J.E., and Zimmet P.Z. The prevention of type 2 diabetes-lifestyle change or pharmacotherapy? A challenge for the 21st century. Diab. Res. Clin. Pract. 59 (2003) 165-180
111. Singh M. Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr. Pharm. Des. 5 (1999) 443-451
112. Skyler J.S. Lessons from studies of insulin pharmacokinetics. Diab. Care 9 (1986) 666-668
113. Skyler J.S., Cefalu W.T., Kourides I.A., Landschulz W.H., Balagtas C.C., Cheng S.L., and Gelfand R.A. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 357 (2001) 331-335
114. Soon-Shiong P. Treatment of type I diabetes using encapsulated islets. Adv. Drug Deliv. Rev. 35 (1999) 259-270
115. Stephen R.L., Petelenz T.J., and Jacobsen S.C. Potential novel methods for insulin administration: I. Iontophoresis. Biomed. Biochim. Acta 43 (1984) 553-558
116. Stern M.P., Williams K., and Haffner S.M. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?. Ann. Intern. Med. 136 (2002) 575-581
117. Stoever J.A., and Palmer J.P. Inhaled insulin and insulin antibodies: a new twist to an old debate. Diab. Technol. Ther. 4 (2002) 157-161
118. Stratford R.E., and Lee V.H.L. Aminopeptidase activity in homogenates of various absorptive mucosae m the albino rabbit: implications in peptide delivery. Int. J. Pharm. 30 (1986) 73-82
119. Street C.N., Sipione S., Helms L., Binette T., Rajotte R.V., Bleackley R.C., and Korbutt G.S. Stem cell-based approaches to solving the problem of tissue supply for islet transplantation in type 1 diabetes. Int. J. Biochem. Cell Biol. 36 (2004) 667-683
120. Tan K.K., Trull A.K., Uttridge J.A., and Wallwork J. Relative bioavailability of cyclosporin from conventional and microemulsion formulations in heart-lung transplant candidates with cystic fibrosis. Eur. J. Clin. Pharmacol. 48 (1995) 285-289
121. Torres-Lugo M., Garcia M., Record R., and Peppas N.A. Physicochemical behavior and cytotoxic effects of p(methacrylic acid-g-ethylene glycol) nanospheres for oral delivery of proteins. J. Control. Rel. 80 (2002) 197-205
122. Veuillez F., Kalia Y.N., Jacques Y., Deshusses J., and Buri P. Factors and strategies for improving buccal absorption of peptides. Eur. J. Pharm. Biopharm. 51 (2001) 93-109
123. Vial T., and Descotes J. Immunosuppressive drugs and cancer. Toxicology 185 (2003) 229-240
124. Wan J., Taub M.E., Shah D., and Shen W.C. Brefeldin A enhances receptor-mediated transcytosis of transferrin in filter-grown Madin-Darby canine kidney cells. J. Biol. Chem. 267 (1992) 13446-13450
125. Woodley J. Bioadhesion: new possibilities for drug administration?. Clin. Pharmacokinet. 40 (2001) 77-84
126. Wu Z.H., Ping Q.N., Wei Y., and Lai J.M. Hypoglycemic efficacy of chitosan-coated insulin liposomes after oral administration in mice. Acta Pharmacol. Sin. 25 (2004) 966-972
127. Xia C.Q., Wang J., and Shen W.C. Hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats. J. Pharmacol. Exp. Ther. 295 (2000) 594-600